The Coronavirus Pandemic: A Pitfall or a Fast Track for Validating Cell Therapy Products?

Volume: 30, Issue: 3, Pages: 119 - 127
Published: Feb 1, 2021
Abstract
The global COVID-19 pandemic has prompted urgent need for potential therapies for severe respiratory consequences resulting from coronavirus infection. New therapeutic agents that will attenuate ongoing inflammation and at the same time promote regeneration of injured lung epithelial cells are urgently needed. Cell-based therapies, primarily involving mesenchymal stromal cells (MSCs) and their derivatives, are currently investigated worldwide...
Paper Details
Title
The Coronavirus Pandemic: A Pitfall or a Fast Track for Validating Cell Therapy Products?
Published Date
Feb 1, 2021
Volume
30
Issue
3
Pages
119 - 127
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.